Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Inspection Record
Shimoga Chemicals — FDA 483 Findings
Inspectors Rachael A Moss · Arsen KarapetyanThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Batch production and control records do not include complete information relating to the production and control of each batch.
The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
Failure to ensure training is regularly conducted by qualified individuals and covers, at a minimum, the particular operations that each employee performs and CGMP as they relate to the employee’s functions.
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Procedures for the cleaning and maintenance of equipment and its release for use in the manufacture of intermediates and API are deficient regarding sufficient detail of the methods, equipment, and materials used in the cleaning and maintenance operation, and the methods of disassembly and reassembly of equipment as necessary to assure proper cleaning and maintenance.
Buildings used in the holding of active pharmaceutical ingredient do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that components and raw materials conform to appropriate standards of identity.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- VitaCare Labs Inc.2025-05-16 · US FDASimilar to finding 4 Batch production and control records do not include complete information relating to the production and control of each batch.
- Granules Pharmaceuticals Inc.2026-04-03 · US FDASimilar to finding 4 Batch production and control records do not include complete information relating to the production and control of each batch.
- SURETEC INNOVATIONS LLC2026-03-05 · US FDASimilar to finding 7 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
- LCC Ltd.2024-03-22 · US FDASimilar to finding 4 Batch production and control records do not include complete information relating to the production and control of each batch.
- Glenmark Pharmaceuticals Inc USA2022-05-19 · US FDASimilar to finding 5 The accuracy, sensitivity, specificity and reproducibility of test methods have not been established and documented.
A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.